氯沙坦钾片联合肾炎康复片用于慢性肾小球肾炎蛋白尿治疗中的效果及安全性分析

Analysis of the effect and safety of losartan potassium tablets combined with Shenyan Kangfu tablets in the treatment of chronic glomerulonephritis proteinuria

目的 探究氯沙坦钾片联合肾炎康复片用于慢性肾小球肾炎蛋白尿治疗中的效果及安全性。方法 86例慢性肾小球肾炎蛋白尿患者作为研究对象,以入院顺序奇偶法分为对照组和观察组,各43例。两组患者入院后均接受基础治疗,在此基础上,对照组实施氯沙坦钾片口服治疗,观察组在对照组基础上联合肾炎康复片口服治疗。比较两组患者治疗效果,治疗前后肾功能指标[血尿素氮(BUN)、24 h尿蛋白定量]水平,治疗前后炎症因子[白细胞诱素-1(LKN-1)、肿瘤坏死因子-α(TNF-α)]水平,不良反应发生情况。结果 观察组治疗总有效率为97.67%,高于对照组的86.05%,差异具有统计学意义(P<0.05)。治疗后,观察组BUN(2.24±0.61)mmol/L、24 h尿蛋白定量(1.69±0.34)g/24 h均低于对照组的(3.87±1.52)mmol/L、(3.87±1.20)g/24 h,差异具有统计学意义(P<0.05)。治疗后,观察组LKN-1(78.28±21.33)pmol/L、TNF-α(29.48±6.75)ng/L均低于对照组的(94.30±24.18)pmol/L、(34.17±5.29)ng/L,差异具有统计学意义(P<0.05)。观察组不良反应发生率为6.98%,与对照组的9.30%比较差异无统计学意义(P>0.05)。结论 慢性肾小球肾炎蛋白尿患者应用氯沙坦钾片联合肾炎康复片治疗,可提升治疗效果,改善患者肾脏功能指标、减轻炎症反应程度,且安全性良好。

Objective To investigate the effect and safety of losartan potassium tablets combined with Shenyan Kangfu tablets in the treatment of chronic glomerulonephritis proteinuria.Methods A total of 86 patients with chronic glomerulonephritis proteinuria were selected as the research subjects,and were divided into the control group and the observation group by the odd-even method of admission order,with 43 cases in each group.Both groups received basic treatment after admission.On this basis,the control group was treated with oral administration of losartan potassium tablets,and the observation group was treated with oral administration of Shenyan Kangfu tablets on the basis of the control group.Both groups were compared in terms of therapeutic effect,renal function indexes[blood urea nitrogen(BUN),24 h urinary protein quantification]before and after treatment,and inflammatory factors[leukotactin-1(LKN-1),tumor cell necrosis factor-α(TNF-α)]before and after treatment,and occurrence of adverse reactions.Results The total effective rate of the observation group was 97.67%,which was higher than 86.05%of the control group,and the difference was statistically significant(P<0.05).After treatment,the BUN(2.24±0.61)mmol/L and 24-h urinary protein quantification(1.69±0.34)g/24 h in the observation group were lower than(3.87±1.52)mmol/L and(3.87±1.20)g/24 h in the control group,and the differences were all statistically significant(P<0.05).After treatment,the LKN-1(78.28±21.33)pmol/L and TNF-α(29.48±6.75)ng/L in the observation group were lower than(94.30±24.18)pmol/L and(34.17±5.29)ng/L in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 6.98%,and there was no significant difference compared with 9.30%in the control group(P>0.05).Conclusion The application of losartan potassium tablets combined with Shenyan Kangfu tablets for patients with chronic glomerulonephritis proteinuria can enhance the therapeutic effect,improve the renal function indexes of the patients,reduce the degree of inflammation,and has good safety.